Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure

Clinical Nephrology

Volumn 54, Issue 1, 2000, Pages 45-53

  Geng, Z ^a   Monier Faugere, M C ^a   Bauss, F ^b   Malluche, H H ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Bisphosphonates; Bone histomorphometry; Mineralized bone histology; Renal failure

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATININE; IBANDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE EROSION; BONE METABOLISM; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG EFFECT; DRUG INDICATION; FEMALE; HYPERPARATHYROIDISM; KIDNEY FAILURE; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RAT;

ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; BONE RESORPTION; CALCIUM; CREATININE; DIPHOSPHONATES; FEMALE; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; RATS; RATS, SPRAGUE-DAWLEY; RENAL OSTEODYSTROPHY;

EID: 0033920576     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartaccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92: 2577-2286
2. Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL 1986 Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1: 27-39
3. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F 1983 Renal failure associated with intravenous diphosphonates (letter). Lancet 1: 471
4. Boyce RW, Paddock CL, Gleason JR, Sletsema WK, Eriksen EF 1995 The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 10: 211-221
5. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 1475-1480
6. Chesnut CH 3rd, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD et al 1995 Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99: 144-152
7. Coburn JW, Slatopolsky E 1991 Vitamin D, parathyroid hormone, and the renal osteodystrophies. In: Brenner BM, Rector FJC (eds) The Kidney. WB Saunders, Philadelphia, pp 2036-2120
8. Dumon JC, Magritte A, Body JJ 1991 Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 15: 257-66
9. Evans C, Braidman I 1994 Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner 26: 95-107
10. Faugere M, Friedler R, Fanti P, Malluche H 1989 Incipient histological and biochemical derangements of renal osteodystrophy. Clin Res 37: 570A
11. Faugere MC, Langub MC, Qi Q, Geng Z, Malluche HH 1997 Parathyroid hormone receptor mRNA expression in bone cells parallels bone turnover in dialyzed patients. J Am Soc Nephrol (Abstract) 8: 551
12. Fleisch H 1993 Bisphosphonates: mechanisms of action and clinical use. Physiology and pharmacology of bone. In: Mundy GR, Martin TJ (eds) Handbook of Experimental Pharmacology. Springer, Berlin, pp 377-418
13. Fleisch H 1995 Bisphosphonates in bone disease. From the laboratory to the patient. The Parthenon Publishing Group, New York
14. Goldner J 1938 A modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol 14: 237-243
15. Hamdy NA, McCloskey EV, Brown CB, Kanis JA 1990 Effects of clodronate in severe hyperparathyroid bone disease in chronic renal failure. Nephron 56: 6-12
16. Hene RJ, Visser WJ, Duursma SA, Raymakers JA, de bos Kuil RJ, Dorhout Mees EJ 1990 No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy. Bone 11: 15-20
17. Hruska KA, Teitelbaum SL 1995 Renal osteodystrophy. N Engl J Med 333: 166-174
18. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478-1487
19. Ito M, Chokki M, Ogino Y, Satomi Y, Azuma Y, Ohta T, Kiyoki M 1998 Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo. Calcif Tissue Int 63: 143-147
20. Kodama H, Yamasaki A, Abe M, Niida S, Hakeda Y, Kawashimu H 1993 Transient recruitment of osteoclasts and expression of their function in osteoporotic (op/op) mice by a single injection of macrophage colony-stimulating factor. J Bone Miner Res 8: 45-50
21. Landman JO, Schweitzer DH, Frolich M, Hamdy NA, Papapoulos SE 1995 Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate. J Clin Endocrinol Metab 80: 524-528
22. Leunissen KM, Vismans FJ, van Leendert RJ, van Hooff JP 1986 Successful treatment of persistent posttransplant hyperparathyroidism with diphosphonate. Transplantation 41: 666-667
23. Malluche HH, Faugere MC 1986 Atlas of Mineralized Bone Histology. Karger, New York
24. Malluche HH, Faugere MC 1990 Renal bone disease 1990: An unmet challenge for the nephrologist. Kidney Int 38: 193-211
25. Malluche HH, Faugere MC, Fanti P, Price PA 1984 Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 26: 869-874
26. Malluche HH, Sherman D, Meyer W, Massry SG 1982 A new semiautomatic method for quantitative static and dynamic bone histology. Calcif Tissue Int 34: 439-448
27. Manaka RC, Malluche HH 1981 A program package for quantitative analysis of histologic structure and remodeling dynamics of bone. Comput Programs Biomed 13: 191-202
28. Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH 1999 Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14: 1768-1778
29. Monier-Faugere M-C, Friedler R, Bauss F, Malluche H 1993 A new bisophosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 8: 1345-1355
30. Muhlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H 1991 BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6: 1003-1011
31. Norusis M 1993 Exploring data. SPSS for Windows Base System User's Guide, Release 6.0. Chicago, IL, SPSS, Inc, 189
32. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche HH, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols and units. J Bone Miner Res 6: 595-610
33. Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ 1996 Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 11: 587-93
34. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095-2105
35. Sawaya P, Malluche HH (1995). Parathyroid hormone, vitamin D and metabolic bone disease in dialysis patients. In: Nissenson AR, Fine RN, Gentile DE (eds) Clinical Dialysis. Appleton and Lange, East Nonwalk, CT, pp 744-776
36. Sellers E, Sharma A, Rodd C 1998 The use of pamidronate in three children with renal disease. Pediatr Nephrol 12: 778-81
37. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H, Inoue T, Tomita A, Nagata Y, Nakashima M, Orimo H 1998 A placebo-controlled, single-blind study to determine trie appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocrinol J 45: 191-201
38. Storm T, Steiniche T, Thamsborg G, Melsen F 1993 Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8: 199-208
39. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd 1996 Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101: 488-501
40. Yap AS, Hockings GI, Fleming SJ, Khafagi FA 1990 Use of aminohydroxypropylidene bisphosphonate (AHPrBP, "APD") for the treatment of hypercalcemia in patients with renal impairment. Clin Nephrol 34: 225-229
41. Yu X, Scholler J, Foged NT 1996 Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone 19: 339-345